Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America T-Cell therapy Market, by End User
1.4.2 North America T-Cell therapy Market, by Indication
1.4.3 North America T-Cell therapy Market, by Therapy Type
1.4.4 North America T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. North America T-Cell therapy Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Cancer Treatment Centers Market by Country
Chapter 5. North America T-Cell therapy Market by Indication
5.1 North America Lymphoma Market by Country
5.2 North America Acute Lymphocytic Leukemia Market by Country
5.3 North America Others Market by Country
Chapter 6. North America T-Cell therapy Market by Therapy Type
6.1 North America CAR T-Cell Therapy Market by Country
6.2 North America T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 North America Axicabtagene Ciloleucel Market by Country
6.2.2 North America Tisagenlecleucel Market by Country
6.2.3 North America Brexucabtagene Autoleucel Market by Country
6.2.4 North America Others Market by Country
6.3 North America T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. North America T-Cell therapy Market by Country
7.1 US T-Cell therapy Market
7.1.1 US T-Cell therapy Market by End User
7.1.2 US T-Cell therapy Market by Indication
7.1.3 US T-Cell therapy Market by Therapy Type
7.1.3.1 US T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 Canada T-Cell therapy Market
7.2.1 Canada T-Cell therapy Market by End User
7.2.2 Canada T-Cell therapy Market by Indication
7.2.3 Canada T-Cell therapy Market by Therapy Type
7.2.3.1 Canada T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 Mexico T-Cell therapy Market
7.3.1 Mexico T-Cell therapy Market by End User
7.3.2 Mexico T-Cell therapy Market by Indication
7.3.3 Mexico T-Cell therapy Market by Therapy Type
7.3.3.1 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Rest of North America T-Cell therapy Market
7.4.1 Rest of North America T-Cell therapy Market by End User
7.4.2 Rest of North America T-Cell therapy Market by Indication
7.4.3 Rest of North America T-Cell therapy Market by Therapy Type
7.4.3.1 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
Unique Offerings 